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Tyrosine kinases and phosphatases establish
the crucial balance of tyrosine phosphoryla-
tion in cellular signaling, but creating specific
inhibitors of protein Tyr phosphatases (PTPs)
remains a challenge. Here, we report the devel-
opment of a potent, selective inhibitor of Myco-
bacterium tuberculosis PtpB, a bacterial PTP
that is secreted into host cells where it disrupts
unidentified signaling pathways. The inhibitor,
(oxalylamino-methylene)-thiophene sulfonamide
(OMTS), showed an IC50 of 440 ± 50 nM and
>60-fold specificity for PtpB over six human
PTPs. The 2 A˚ resolution crystal structure of
PtpB in complex with OMTS revealed a large re-
arrangement of the enzyme, with some residues
shifting >27 A˚ relative to the PtpB:PO4 complex.
Extensive contacts with the catalytic loop pro-
vide a potential basis for inhibitor selectivity.
Two OMTS molecules bound adjacent to each
other, raising the possibility of a second sub-
strate phosphotyrosine binding site in PtpB. The
PtpB:OMTS structure provides an unanticipated
framework to guide inhibitor improvement.
INTRODUCTION
Tyrosine phosphorylation broadly regulates the physiol-
ogy of eukaryotic cells. While pharmaceuticals targeting
tyrosine kinases are already on the market, development
of drugs that target any of the 85 human protein tyrosine
phosphatases (PTPs) is at an earlier stage. Given the di-
verse roles of phosphatases in cellular homeostasis, in-
hibitor specificity is crucial to minimize side effects. Two
approaches to developing PTP inhibitors have been re-
ported. One recent strategy relies on natural products to
guide inhibitor development (Noren-Muller et al., 2006).
In contrast, many synthetic PTP inhibitors are based on
a pTyr mimetic as the central building block (Bialy and
Waldmann, 2005). This latter approach has the advantage
that it is relatively easy to find starting points for inhibitors.
However, the phosphotyrosine mimetic poses a challengeStructure 15,to introduce sufficient selectivity, because the phospho-
tyrosine-binding pockets of different PTP enzymes are
similar. This problem is reinforced by the observation
that isolated PTP catalytic domains often exhibit modest
substrate specificity, with cellular localization and the ac-
tivities of appended substrate-binding domains enhanc-
ing selectivity in vivo (Barford et al., 1998).
The central roles of PTPs in eukaryotic signaling are ex-
ploited by some pathogenic bacteria, which produce and
secrete PTPs to attenuate host immune defenses (DeVin-
ney et al., 2000). To explore approaches to develop selec-
tive inhibitors against such bacterial PTPs, we targeted
the PtpB enzyme that functions as a key secreted viru-
lence factor in Mycobacterium tuberculosis (Mtb). Tuber-
culosis is a major cause of worldwide mortality from infec-
tious disease, prompting a search for innovative targets
for therapeutics. New targets are needed not only to
speed the course of treatment, but also to attack emerg-
ing multidrug-resistant Mtb strains (Nachega and Chais-
son, 2003) and to treat tuberculosis in AIDS patients.
Among the proteins secreted into the host cell by Mtb
are PtpA and PtpB, which are thought to interfere with
host signaling pathways. Importantly, the genetic knock-
out of ptpB attenuated growth ofMtb in activated macro-
phages and guinea pigs (Singh et al., 2003). This study
implies that a specific PtpB inhibitor may speed treatment
by enabling macrophages to target the intracellular res-
ervoirs of the bacterium that remain after treatment with
current drugs.
The crystal structure of the PtpB:PO4 product complex
established this enzyme as amember of a novel subfamily
of ‘‘conventional’’ tyrosine phosphatases that exclusively
act on phosphotyrosine (Grundner et al., 2005). The con-
ventional PTPs include other bacterial virulence factors,
such as YopH from Yersinia spec. as well as hundreds of
eukaryotic enzymes. Conventional PTPs share core struc-
tural features, such as a catalytic domain containing
a four-stranded parallel b sheet that connects to a helix
through the so-called P loop. The P loop harbors the cat-
alytic cysteine nucleophile within the invariant sequence
HCX5R. Other residues important for catalysis are found
in PTPs with varying degrees of conservation, among
them the WPD loop containing the general acid and the
pTyr recognition loop (the Q loop) that coordinates the
substrate pTyr and a catalytic water molecule (Barford499–509, April 2007 ª2007 Elsevier Ltd All rights reserved 499
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PtpB-Inhibitor RecognitionFigure 1. Inhibitory Activity of OMTS on
Phosphatases
(A) Structure of OMTS.
(B) IC50 determination. Inhibitory activity of
increasing concentrations of OMTS was as-
sessed on PtpB, Glepp1, and PTP1B phospha-
tases. Mean values and standard deviations
are represented. An IC50 value for PtpB of
0.44 mM was calculated from this experiment.
(C) Selectivity of OMTS on a panel of phospha-
tases. Results are expressed as percent inhibi-
tion at 10 mM OMTS.et al., 1998). Most PTPs also contain cellular localization
signals that regulate their activity and confer tighter sub-
strate specificity (Barford et al., 1998).
The structure of the Mtb PtpB:PO4 complex revealed
two major differences from this standard architecture that
might be exploited to develop selective inhibitors. First,
PtpB lacks a targeting domain, suggesting that substrate
specificity is determined by direct interactions of the cat-
alytic domain. Second, the PtpB:PO4 structure revealed
an unexpected two-helix lid that completely covered the
active site and blocked substrate turnover in the crystals
(Grundner et al., 2005). The enzyme is active in solution,
however, suggesting that the lid opens readily to permit li-
gand binding and release. Because reversible oxidation of
the catalytic cysteine has emerged as a potentially general
mechanism of PTP regulation (Salmeen et al., 2003; Groen
et al., 2005), we hypothesized that the PtpB lid might pro-
tect Cys160 from inactivation by reactive oxygen and ni-
trogen species released inmacrophages during the oxida-
tive burst (Grundner et al., 2005). This hypothesis was
supported by the observation that PtpB resists oxidative
inactivation better than PtpA or other phosphatases that
do not have a comparable lid. The PtpB:PO4 structure
identified autoinhibition as the crucial feature determining
PtpB function but revealed little about the mechanism by
which substrates access the active site. Due to the disor-
der of a 30-residue loop, the previous structure also fell
short of fully defining the active-site cavity.500 Structure 15, 499–509, April 2007 ª2007 Elsevier Ltd All righHere, we describe the structure and the molecular
mechanism of recognition of a novel competitive inhibitor
of PtpB, (oxalylamino-methylene)-thiophene sulfonamide
(OMTS). The crystal structure of PtpB in complex with
OMTS reveals that the enzyme undergoes a large confor-
mational change, allowing the inhibitor to bind deep in
the active-site pocket. Compared to the PtpB:PO4 com-
plex, there are two major changes. First, inhibitor binding
promotes a large hingemotion of one helix in the lid to form
a hydrophobic hairpin and a channel that leads to the cat-
alytic cysteine. Second, the 30-residue, disordered loop
folds to formanewhelixbordering theactivesite.Unexpect-
edly, two molecules of OMTS bound one molecule of PtpB
in solution and in the crystal structure. The binding of two
phosphotyrosine (pTyr) mimetics is reminiscent of binding
of peptides containing two phosphotyrosines to PTP1B
and PTPL1 (Puius et al., 1997; Salmeen et al., 2000; Villa
et al., 2005) and raises the possibility of a secondpTyr bind-
ing site on PtpB.
RESULTS
Inhibitor Design and Binding Properties
The structural conservation of the PtpB active site led us
to search for inhibitors based on scaffolds previously used
to target eukaryotic PTPs. Initial hits were identified in a
screen of a library of oxamic acid derivatives by using a ho-
mogeneous plate assay (D.S. et al., unpublished data).ts reserved
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PtpB-Inhibitor RecognitionOMTS (Figure 1A) inhibited PtpB with an IC50 value of
0.44 ± 0.05 mM (Figure 1B) but was not effective against a
panel of three human PTPs (Figure 1B). At the highest
concentration tested (30 mM), OMTS was inactive on
PTP1B (5% inhibition) and displayed only 45% inhibition
of Glepp1. On a broader panel of phosphatases tested
at 10 mM inhibitor where PtpB was 95% inhibited, OMTS
showed less than 10% inhibition not only on PTP1B and
Glepp1 but also on PTPb, PTP-H1, and PAC1 (Figure 1C).
The mode of PtpB inhibition by OMTS was determined
in a competition study, varying simultaneously the sub-
strate and inhibitor concentrations. The compound be-
haved as a classic competitive inhibitor (Figures 2A and
2B), affecting the apparent Km value, while Vmax was
unchanged. An apparent Ki value of 0.33 ± 0.04 mM was
calculated from these experiments.
PtpB:OMTS Structure Determination
In the PtpB:PO4 complex, a lid comprising helices a7, a8,
and the connecting loop completely sequestered the ac-
tive site from solvent (Grundner et al., 2005). Because it
was unlikely that the crystal lattice of the PtpB:PO4 com-
Figure 2. Inhibition Kinetics
(A) Michaelis-Menten representation of PtpB inhibition. RFU, relative
fluorescence units.
(B) Lineweaver-Burk representation of PtpB activity at increasing con-
centrations of inhibitor. Both representations indicate that OMTS is
a competitive inhibitor of PtpB.Structure 15,plex could accommodate inhibitor binding, we initiated a
screen for new crystallization conditions. The PtpB:OMTS
complex produced a new crystal form with two enzyme
molecules in the asymmetric unit. The structure of the
complex was determined by molecular replacement and
refined to R/Rfree values of 0.189/0.249 at 2 A˚ resolution
(Table 1 and Figure 3). The two independent copies of
PtpB adopted similar structures with a root-mean-square
deviation (rmsd) between Ca atoms of 0.56 A˚. The final
model includes residues 4–104 and 112–276 for molecule
A and residues 4–104 and 117–276 for molecule B. No
clear electron density was visible for residues 105–111
and 105–116 formolecules A andB, respectively. For each
PtpB chain, two inhibitor molecules were built into well-
defined electron density, and 360 ordered waters were
modeled in the asymmetric unit.
Conformational Changes in the PtpB:OMTS
Complex
Compared to the closed structure of the PO4 complex
(PDB ID 1YWF), the structure of the PtpB:OMTS complex
showed threemajor structural differences.Most notably, a
large, en bloc movement of helix a8 created a paddle-like
helical hairpin (a7-a8) with an exposed hydrophobic sur-
face extending away from the catalytic domain (Figures
Table 1. Data Collection and Refinement Statistics
Data Collection and Phasing
Crystal symmetry P212121
Unit cell a = 74.4, b = 72.5,
c = 96.1, a = b = g = 90
Resolution (A˚) 50–2.0
Completeness (%) 97.1 (79.6)
Multiplicity 3.6 (1.9)
Rmerge (%)
a 3.4
hI/sIi 30.1 (7.0)
Mosaicity () 0.299
Refinement
Resolution (A˚) 50–2
Reflections 34,740
Rcryst
b/Rfree (%) 18.9/ 24.9
Rms D bondsc (A˚) 0.013
Rms D anglesc () 1.5
Average B factor (A˚2) 14.4
Main-Chain Dihedral Angles (%)
Most favored 90.8
Allowed 9.2
Parentheses denote values for the highest resolution shell.
a Rmerge =
PjI  hIij/PI; I, intensity.
b Rcryst =
PjFo  Fcalcj/
P
Fo; Fo, bserved structure-factor
amplitude; Fcalc, calculated structure-factor amplitude.
cRoot-mean-square deviations from ideal values.499–509, April 2007 ª2007 Elsevier Ltd All rights reserved 501
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PtpB-Inhibitor RecognitionFigure 3. Overall Structure of the
PtpB:OMTS Complex
(A) Stereo representation of the simulated-
annealing, Fo-Fc omit map of OMTS bound in
the PtpB active site contoured at 3 s. Electron
density for the proximal and the chlorobenzyl
group of the distal OMTS is shown.
(B) Two molecules of OMTS bind in the PtpB
active site. Helix a8, part of the autoinhibitory
lid, rotated around Ser228 by 90 to open
the active site. Residues 88–103 form helix
a3A not seen in the PtpB:PO4 structure.
Helices a3, a3A, a4, and the a7-a8 hairpin
ring the active-site cavity.4A, 5A, and 5B). Second, residues 85–104, which were
disordered in the PtpB:PO4 complex crystals, formed
a new a helix (called a3A) adjacent to the active site pocket
(Figure 5C). Third, formation of helix a3A also inverted the
adjacent WPD loop (FPD in PtpB) that contains a con-
served Asp residue that functions as a general acid in
PTPs. The loop projects in the opposite direction from
that in the PtpB:PO4 complex (Figure 5C).
In the PtpB:PO4 complex, the closed lid made many
intramolecular interactions with the rest of the protein,
including salt bridges (Glu214:Arg63, Glu218:Arg166,
Lys224:Asp85, and Asp229:Arg200) and hydrophobic
contacts exemplified by the burial of Phe222. The super-
position of the PtpB:PO4 and the PtpB:OMTS structures
revealed that a 90 rotation of helix a8 around Ser228
eliminated all of these contacts (Figures 5A and B). This
shift projected helix a8 against helix a7 and created an502 Structure 15, 499–509, April 2007 ª2007 Elsevier Ltd All righopening to the active-site cysteine. This rotation moved
the tip of helix a8 by 20 A˚ from its position in the closed
state. Several side chains that are deeply buried in the
closed structure (e.g., Glu218 and Phe222) moved up to
28 A˚ (Figure 5B).
The C terminus of helix a7 was pulled slightly (2 A˚) to-
ward the active site by the rotation of helix a8. These
movements exposed a large hydrophobic surface on the
face of the a7-a8 hairpin that lines one side of the entrance
to the active site (Ile203, Ile207, Thr213, Phe211, Leu215,
Val219, Val220 [Figure 4A]). With the lid in this position, the
inhibitors filled the narrow channel to the catalytic Cys160,
and this close fit of OMTS in the channelmakes it apparent
that additional conformational changes would be needed
for the inhibitor molecules to bind and release.
In the PtpB:PO4 complex, no interpretable electron den-
sity was visible for the entire region between Asp85 andts reserved
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PtpB-Inhibitor RecognitionSer117. The large conformational changes upon OMTS
binding were accompanied by the formation of a helix
a3A encompassing residues Asp88 to Thr103. The posi-
tion of helix a8 in the closed structure partially overlaps
with the position of the C terminus of the new helix a3A
of the PtpB:OMTS complex, suggesting that these confor-
mational elements aremutually exclusive. Helix a3A packs
on top of helix a4 and forms the side of the active-site
cavity, deepening the pocket to up to 20 A˚ from the helix
backbone to the catalytic Cys160. Formation of helix
a3A reveals the full extent of the active-site cavity, which
is ringed by helices a3, helix a3A, and the a7-a8 hairpin
(Figure 3B).
Inhibitor binding was associated with a change in con-
formation of the Asp82 in the FPD loop compared to the
closed PtpB:PO4 complex (Figure 5C). The formation of
the helix a3A, which immediately follows the FPD loop,
is probably coupled to the rearrangement in the loop. In
the PtpB:OMTS complex, Pro81 was flipped, and this
change positioned the general acid Asp82 away from
the active site. Asp82 moved over 13 A˚ from its position
in the closed structure (Figure 5C).
To investigate the folding transition of helix a3A in solu-
tion, we probed the sensitivity of the protein to limited pro-
teolysis. OMTS binding led to an overall protection of PtpB
from proteolysis (Figure 6). Trypsin and thermolysin were
predicted to cleave PtpB at positions within helix a3A, pro-
ducing proteolytic fragments of 11 and 19 kD. When
limited proteolysis of PtpB was carried out in the absence
of inhibitor, the two expected fragments were readily gen-
erated (Figure 6). Mass spectrometry (data not shown) con-
firmed that these fragments arose from cleavages in the
b3-a4 loop, which was disordered in the crystal structure
of the PtpB:PO4 complex. Production of the two frag-
ments peaked after 30 min incubation with trypsin and
after 2 hr with thermolysin. When proteolysis was per-
formed in the presence of 1 mM OMTS, the cleavage of
helix a3A was inhibited. Trypsin cleavage in the b3-a4
loop peaked after 3 hr, and thermolysin cleavage required
an overnight incubation at 37C (Figure 6A and data not
shown). OMTS protected PtpB from thermolysin cleavage
in the b3-a4 loop in a concentration-dependent manner
(Figure 6B). This protection suggests that inhibitor binding
stabilizes and promotes folding of helix a3A.
Inhibitor Interactions with PtpB
Unexpectedly, two molecules of the inhibitor bound in the
active site, in direct contact with each other (Figure 3). The
inhibitor proximal to the catalytic Cys160 was completely
buried. The second, distal inhibitor was wedged in by the
newly formed helix a3A and helices a7 and a8. The prox-
imal inhibitor bound in identical positions and made the
same interactions in the two independent PtpB com-
plexes in the asymmetric unit. The oxalylamino carboxyl
group occupied the position of the PO4 in the PtpB:PO4
complex. The oxalylamino group formed six hydrogen
bonds to Cys160, Ala162, Lys164, and Arg166 (Figure 4B),
and the negative charge of this pTyr mimetic also was
complementary to the helix dipole of helix a5. The inhibitorStructure 15,sulfonyl group formed another hydrogen bond to a buried
water. The proximal inhibitor was surrounded by PtpB,
making contacts with over 20 residues of the enzyme
(Figures 4A and 4B), including the entire P loop (residues
160–166).
The two inhibitor molecules formed an extensive hydro-
phobic network with aromatic side chains and each other.
The two inhibitors contacted each other through an edge-
to-face interaction of the chlorobenzyl groups. In addition,
the terminal benzyl groups of the proximal inhibitor inter-
acted with the thiophene group of the distal inhibitor
(Figure 3A). The distal inhibitor looped over Phe98, projec-
ting from the newly formed helix a3A toward the active
site. The oxalylamino group bound in a positively charged
pocket bordered by three Arg side chains (Arg59, Arg64,
and Arg210) (Figure 4C). Binding of the distal inhibitor dif-
fered slightly between molecules A and B, which reflected
differences in intermolecular contacts in the crystals
(Figure 4C). As a result of the different crystal contacts,
the Phe211 side chains in the a7-a8 helical hairpin adop-
ted different rotamers in the two PtpB molecules. The dis-
tal inhibitor makes fewer interactions than the proximal
one. The oxalylamino carboxyl group formed two hydro-
gen bonds with Arg210, and Arg59 formed another hy-
drogen bond to the sulfonyl group. The terminal benzyl
groups made hydrophobic interactions with Phe98,
Leu102, and Phe211.
The presence of the distal inhibitor in the PtpB:OMTS
structure raised the question of whether two inhibitor mol-
ecules also bind in solution, particularly since the distal in-
hibitor participated in intermolecular crystal contacts. To
determine the stoichiometry of OMTS binding in solution,
we performed isothermal titration calorimetry (Figure 8).
The data provided evidence for binding of two inhibitor
molecules per PtpB, with apparent dissociation constants
of 73 nM and 1.2 mM.Unexpectedly, the binding of the first
inhibitor showed a positive enthalpy change at room tem-
perature, indicating that the reaction is entropy driven. The
binding of the second OMTS molecule showed a conven-
tional, enthalpy-driven isotherm.
DISCUSSION
The attenuated growth and virulence of a ptpB gene
knockout strain of Mtb in IFNg-stimulated macrophages
and in guinea pigs afforded a compelling rationale to
target PtpB to develop new drugs to treat TB (Singh
et al., 2003). Moreover, PtpB also provides an attractive
target because the enzyme functions outside the bacte-
rium in the host cells, eliminating the need for inhibitors
to traverse the relatively impermeable bacterial envelope.
The structural similarities of PtpB and mammalian PTPs,
as well as the discovery of chemically related inhibitors
that target PtpB and mammalian PTPs (Noren-Muller
et al., 2006), suggested that traditional chemical pTyr mi-
metics could be adapted to inhibit this bacterial homolog.
Here, we identified a potent competitive inhibitor of
PtpB based on the oxamic acid scaffold previously used
to target mammalian PTPs. While many oxalylamino499–509, April 2007 ª2007 Elsevier Ltd All rights reserved 503
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PtpB-Inhibitor RecognitionFigure 4. Interactions between OMTS and PtpB
(A) Electrostatic surface representation of PtpB generated with APBS (Baker et al., 2001) (blue, positive potential; red, negative potential) and stick
representation of the inhibitors shows the depth of the active-site cleft. The distal OMTS molecule is more exposed, while the inhibitor proximal to
Cys160 is buried. The approximate locations of hydrophobic residues lining the surface of the helix-a7-a8 hairpin are indicated.
(B) Schematic drawing of interactions between the proximal inhibitor and the PtpB catalytic site (generatedwith LIGPLOT and editedmanually). Water
391 contacting the sulfonyl group was omitted. Over 20 PtpB residues contact the proximal inhibitor.504 Structure 15, 499–509, April 2007 ª2007 Elsevier Ltd All rights reserved
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PtpB-Inhibitor RecognitionFigure 5. Movement of Helix a8 Allows Access to the Active Site
(A) Surface representation of the PtpB:OMTS structure (blue) shows the opening to the active site and the position of helix a3A that blocks access to
the active site in the PtpB:PO4 structure (orange).
(B) Movement of selected residues in helix a8 upon inhibitor binding. Many residues buried in the PtpB:PO4 complex are exposed upon OMTS bind-
ing. Phe222, which mimics the substrate pTyr side chain in the autoinhibited PtpB:PO4 complex, shifts almost 16 A˚. Glu218, which forms a salt bridge
with the conserved, PO4-liganding Arg166 in the P loop, moves almost 28 A˚ in the PtpB:OMTS complex.
(C) Helix a3A folds and theWPD loop flips upon inhibitor binding. The general acid Asp82moves by >13 A˚ in the PtpB:OMTS complex (blue) compared
to the product complex (orange). The new helix a3A (blue) and the proximal inhibitor (gray) clash with the WPD loop of the closed structure (orange).compounds bind PTPs relatively nonspecifically, OMTS
showed >60-fold selectivity for PtpB over a panel of hu-
man PTPs (PTP1B, Pac1, Glepp1, and PTPH1). Inhibitor
binding was associated with the folding of helix a3A and
a large conformational change in helix a8 (Figure 5) that to-
gether established a deep channel to the active site. Helix
a8 packed parallel to the end of a7, forming a paddle with
an extensive hydrophobic surface (Figure 4A) that is posi-
tioned to mediate protein substrate recognition.
Interestingly, two inhibitor molecules bound to PtpB in
solution and in the crystals. The inhibitor molecule proxi-Structure 15,mal to the catalytic site was buried in the crystal structure
of the PtpB:OMTS complex, making extensive interac-
tions that contribute to binding affinity and specificity.
The intimate contacts of OMTS with the entire P loop,
for example, provide clues about the basis for specificity
of PtpB:OMTS recognition. Three of the six P loop resi-
dues that contact OMTS are unique to PtpB compared
to the human PTPs that were not significantly inhibited
(Figure 7A). While PtpB Phe161 in the position adjacent
to the catalytic cysteine made hydrophobic contacts, the
human PTPs PTP1B, PTProt (Glepp1), PTPH1 have a Ser(C) The distal inhibitor binds with the oxamic acid group surrounded by Arg side chains. This cluster of Arg side chains provides a chemically reason-
able site for the binding of a second pTyr residue to PtpB. Differences between the structures of the distal inhibitors in the two complexes in the
asymmetric unit are shown.499–509, April 2007 ª2007 Elsevier Ltd All rights reserved 505
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PtpB-Inhibitor Recognitionor Gln (Pac1) in this position. Similarly, Lys164 (Ile or Val in
the human PTPs) and Asp165 (Gly in human PTPs) repre-
sent nonconservative changes from the human consen-
sus residues. The consensus among the human P loop
residues extends to other PTPs such as LAR, PTPa, and
CD45 (Figure 7B). This pattern suggests that OMTS is
likely to show specificity for PtpB over PTPs in addition
to the ones tested in this study. The oxalylamino group
of OMTS also bound to PtpB in a different orientation
compared to other PTP inhibitors based on this scaffold
(Andersen et al., 2000) (Figure 7B). These subtle structural
differences also may contribute to the observed specific-
ity of OMTS for PtpB.
The distal inhibitor packed on top of the proximal in-
hibitor. Our solution measurements suggested that the
second inhibitor molecule binds in solution with 16-fold
weaker affinity than the first (Figure 8). The entropy-driven
character of the first binding event is consistent with
a model in which desolvation of charges and hydrophobic
groups (Yin et al., 2006) and conformational transitions in
the lid dominate the binding thermodynamics. The second
inhibitor molecule highlights the space that is available for
extending the inhibitors to improve binding. Covalently
linking features of the two OMTS molecules might further
enhance affinity and specificity and help satisfy pharma-
cological requirements.
The binding of two molecules of OMTS was reminiscent
of the binding of diphosphorylated substrate peptides to
mammalian PTPs such as PTP1B. The interaction of the
pTyr mimic of the distal inhibitor was chemically reason-
able—the oxalylamino group bound in a surface pocket
ringed by three Arg residues (Figure 4C). To assess the
plausibility of the binding of substrates with two pTyr res-
idues, we compared the PtpB:OMTS complex with the
PTP1B complex with a pTyr-pTyr substrate motif (Sal-
meen et al., 2000). The distal OMTS molecule bound in a
different direction on the PtpB surface compared to the
nonsubstrate pTyr in the PTP1B complex (Figure 7C).
Nonetheless, the distance between bound tyrosine phos-
phates in the complex of PTP1B with a peptide substrate
complex (12.7 A˚) closely matched the distance between
the carboxylate oxygens (13.1 A˚) in the two OMTS mole-
cules bound to PtpB. This similarity raises the possibility
that PtpB may recognize substrates with adjacent pTyr
residues.
More directly, the binding of OMTS begins to define the
plasticity of PtpB that underlies the seemingly paradoxical
functional model in which the lid simultaneously protects
the enzyme from oxidative inactivation and enables sub-
strate access to the active site (Grundner et al., 2005).
Although the closed structure of the PtpB:PO4 complex
revealed elements of structural strain (such as buried
charges and a segment of two full turns of 310 helix em-
bedded in helix a7) that might potentiate movement of
the lid, the mode of opening was not apparent. OMTS ac-
cesses the catalytic Cys160 by a deceptively simple hinge
motion of helix a8 and smaller adjustments of nearby res-
idues (Figure 5). The large movement of helix a8 leaves
space for the folding of the new helix a3A. Since OMTS506 Structure 15, 499–509, April 2007 ª2007 Elsevier Ltd All riprotects this helix from proteolytic cleavage in solution,
helix a3A apparently is stabilized upon OMTS binding.
In turn, helix a3A established a deep channel to the ac-
tive site and flipped the general acid, Asp82, into a nonpro-
ductive conformation that is too far from the active site to
participate in catalysis. The formation of helix a3A at the
same time as the FPD loop movement suggests that the
helix might be disordered until substrate binds. This inher-
ent flexibility presents a somewhat larger andmore pliable
opening for initial substrate docking. This idea is consis-
tent with the finding that the channel occupied by the
OMTS molecules is too narrow to enable OMTS binding
and release. While the space occupied by the two inhibitor
molecules may indicate the path of a polypeptide sub-
strate, the channel is a dead end. This lack of an exit chan-
nel beyond Cys160 suggests that even larger structural
Figure 6. OMTS Protects the b3-a4 Loop of PtpB from Pro-
teolysis
(A) SDS-PAGE gels show the course of partial proteolytic cleavage
with trypsin (top) and thermolysin (bottom) in the absence (left) and
presence (right) of 1 mM OMTS. The generation of the cleavage prod-
ucts at 11 and 19 kD (asterisks) is inhibited by the presence of OMTS.
Mass spectrometry of these bands extracted from the gels showed
that these products result from cleavage at sites in the b3-a4 loop
(data not shown). OMTS slowed cleavage of this segment by both pro-
teases, consistent with the folding of helix a3A in the PtpB:OMTS
structure. A fragment of slightly smaller molecular mass than PtpB
resulted from cleavage of the six-histidine tag.
(B) PtpB cleavage by thermolysin is inhibited with increasing OMTS
concentration.ghts reserved
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PtpB-Inhibitor RecognitionFigure 7. Basis for the Selectivity of
OMTS Recognition
(A) Three (red) of the six residues in the P
loop that make contacts to OMTS are unique in
PtpB compared to a variety of human conven-
tional PTPs.
(B) Binding of the proximal OMTS (green) in the
PtpB active site (blue) shows an alternative ori-
entation of the oxalylamino group compared to
the binding of a 2-(oxalyl-amino)-benzoic acid
derivative (yellow) to PTP1B (PDB ID 1C88).
(C) Comparison of the phosphotyrosine bind-
ing sites of PTP1B (PDB ID 1G1H) and the
two OMTS binding sites in PtpB. The second
binding sites are positioned in opposite direc-
tions from the catalytic Cys in the two PTPs.
A similar distance of13 A˚ separates the adja-
cent pTyr phosphates bound to PTP1B and the
oxamic acid groups of the proximal (site 1) and
distal (site 2) OMTS molecules bound to PtpB.changes are needed both to fully open the lid and to
accommodate protein substrates. Thus, the PtpB:OMTS
complex represents a second closed structure distinctStructure 15from the PtpB:PO4 complex. While the movement of helix
a8 reveals one crucial mechanism of lid opening, the nar-
row, dead-end binding channel suggests that even largerFigure 8. Binding Characteristics of
OMTS
Isothermal titration calorimetry data for the
binding of OMTS to PtpB and fitting to a two-
binding site model. The biphasic fitting curve
shows entropy-driven binding of the proximal
and enthalpy-driven binding of the distal
OMTS. Thermodynamic parameters for the
proximal (OMTS 1) and distal (OMTS 2) inhibi-
tor at 25C are given., 499–509, April 2007 ª2007 Elsevier Ltd All rights reserved 507
Structure
PtpB-Inhibitor Recognitionchanges are required to access the open state of the
enzyme.
EXPERIMENTAL PROCEDURES
PtpB Expression and Purification
PtpBwas cloned in frame with an N-terminal His-tag as described pre-
viously (Grundner et al., 2005). The full-length, His-tagged PtpB protein
was expressed in BL21 (DE3)-CodonPlus cells (Stratagene) grown in
Terrific Broth containing 50 mg/ml kanamycin and 34 mg/ml chloram-
phenicol at 37C to an OD600 of 0.8. After adding IPTG to 20 mM, the
cultures were grown for an additional 20 hr at 20C. The cells were
harvested by centrifugation and resuspended in 20 mM Tris (pH 7.5),
100 mM NaCl. The cells were lysed by sonication on ice and centri-
fuged at 15,000 3 g for 1 hr. PtpB was purified by immobilized metal
affinity chromatography and size exclusion chromatography (Super-
dex S75). The protein was eluted from the size exclusion column with
20 mM Tris (pH 7.5), 50 mM NaCl, and was concentrated to 10 mg/ml.
Measurement of Phosphatase Activity and Inhibition
Unless otherwise stated, chemicals were purchased from Sigma-
Fluka. DiFMUP (6,8-Difluoro-4-methyumbelliferyl phosphate) was
from Molecular Probes/Invitrogen. Ninety-six-well plates were from
Corning Incorporated. OMTS ([(3-chlorobenzyl)([5-([(3,3-diphenylpro-
pyl)amino]sulfonyl)-2-thienyl]methyl)amino][oxo]acetic acid) was syn-
thesized at Serono International (D.S. et al., unpublished data).
Phosphatase assayswere carried out in 96-well plates containing 5 ml
of diluted compound or solvent (100% DMSO) in each well. Fifty-five
microliters of DiFMUP (72.7 mM) diluted in PTPB buffer (20 mM Bis
Tris HCl [pH 6.6], 0.1% Brij 35, 1 mM DL-dithiothreitol) was added, fol-
lowed by 40 ml of recombinant PtpB (50 ng/ml) diluted in PTPB buffer in
order to start the reaction. After 45 min at room temperature, fluores-
cence intensity (FI) was measured (excitation at 355 nm and emission
at 460 nm for 0.2 s) on a Perkin-Elmer Fusion spectrofluorimeter (Per-
kin-Elmer Life Sciences). Negative controls were performed in the ab-
sence of enzyme, and positive controls were carried out in the pres-
ence of enzyme without compound. The percentage of activity was
calculated according to the formula: % activity = 100 3 (FIcompound 
FIlow control)/(FIhigh control  FIlow control). IC50 values were determined
in triplicate in two independent experiments. For competition studies,
concentrations of both DiFMUP and inhibitor were varied and fluores-
cence intensity was measured in kinetic mode on a Fluostar (BMG
Labtech Gmbh) spectrofluorimeter. The Ki value for OMTS was deter-
mined by varying substrate and inhibitor concentration and calculated
from the intersection with the x axis of the reciprocal plot of the slopes
of the Lineweaver-Burke plots versus inhibitor concentration. Data
were analyzed with the Prism3 software (Graphpad Software, Inc.).
For selectivity studies, assays were performed at pH 7.5 as de-
scribed for PtpB with a DiFMUP concentration corresponding to the
Km of the enzyme studied. The GST-tagged catalytic domain of hu-
man phosphatases PTP1B, PTPb, PTP-H1, PAC1, and Glepp1 were
cloned, expressed in E. coli, and purified by affinity on a GSH column
as described (Wa¨lchli et al., 2000, Pasquali et al., 2003).
Crystallization
The PtpB-OMTS complex was crystallized at 18C by sitting drop va-
por diffusion. The inhibitor was dissolved in DMSO and added to PtpB
(10 mg/ml, 330 mM) to achieve a final inhibitor concentration of
0.6 mM. PtpB-OMTS solution was mixed with an equal volume of crys-
tallization solution (0.1 M ammonium acetate, 0.1 M Bis-Tris [pH 5.5],
17% PEG 10,000, 0.5% b-octylglucoside) and equilibrated against
500 ml of crystallization solution.
X-Ray Data Collection and Analysis
Crystals were briefly immersed in crystallization solution containing
25% glycerol, mounted on a loop, and frozen in liquid nitrogen. Data
were collected to a resolution of 2 A˚ at the Lawrence Berkeley National508 Structure 15, 499–509, April 2007 ª2007 Elsevier Ltd All righLaboratory Advanced Light Source Beamline 8.3.1. The data were
reduced with HKL2000 (Otwinowski and Minor, 1997). Phases were
obtained by molecular replacement with MolRep (Vagin and Isupov,
2001). The search model was built from the coordinates of the
PtpB:PO4 complex (1YWF) by deleting the phosphate and the lid seg-
ment (helices a7 and a8). The initial model was built with ARP/wARP
(Morris et al., 2002) followed by manual building with Coot (Emsley
and Cowtan, 2004). Refinement with REFMAC (Murshudov et al.,
1997) was performed between cycles of manual building. Water mole-
cules were identified with Coot. After refinement of the protein and wa-
ter molecules, unambiguous electron density for two molecules of in-
hibitor per PtpBwas apparent. The inhibitor was built in O (Jones et al.,
1991) with coordinates and ideal bond and angle parameters gener-
ated with PRODRG (Schuettelkopf and van Aalten, 2004) andmodified
as required. The final model was refined with REFMAC to an R factor
of 18.9% and a free R factor of 24.9%. PROCHECK and MolProbity
were used for structure validation.
Isothermal Titration Calorimetry
For isothermal titration calorimetry, the PtpB concentration was deter-
mined photometrically in 6 M guanidinium hydrochloride and by Coo-
massie blue visualization after SDS-PAGE. Inhibitor was diluted to 400
mM in 20 mM Tris (pH 7.5), 50 mMNaCl, resulting in a final DMSO con-
centration of 4%. PtpB was diluted in the same buffer with 4% DMSO
to obtain a 20 mM protein concentration. Measurements were carried
out in a VP-ITC instrument (MicroCal) at 25C by injecting inhibitor
into PtpB. Inhibitor-into-buffer and buffer-into-PtpB injections were
performed to control for solvation and dilution effects. The data were
fitted to a two binding site model with the Origin software package
(MicroCal).
Limited Proteolysis and Mass Spectrometry
Recombinant PtpBwas incubatedwith 1:1000 (w/w) trypsin or thermo-
lysin (Sigma) in 20 mM Tris (pH 7.5), 50 mM NaCl at room temperature
or 37C. Inhibitor in 100%DMSOor the same volume of DMSOwithout
inhibitor was added to the protein before addition of protease. Sam-
ples were taken at various time points, and proteolysis was stopped
by the addition of SDS-PAGE loading buffer to achieve a final SDS con-
centration of 1%. The samples were run on a 14% Tris-glycine gel and
stained with Coomassie blue. The molecular masses and trypsin
cleavage sites of the 11 and 19 kD fragments were determined by elec-
trospray ionization-ion trap mass spectrometry (Bruker-Agilent).
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